City Therapeutics
Cambridge
About City Therapeutics
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achieve better patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $135.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2024)
- Website: citytx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/city-therapeutics-58734 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.